PMID- 33119218
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1399-3046 (Electronic)
IS  - 1397-3142 (Linking)
VI  - 24
IP  - 7
DP  - 2020 Nov
TI  - Current practice of antithrombotic prophylaxis in pediatric kidney 
      transplantation-Results of an international survey on behalf of the European 
      Society for Paediatric Nephrology.
PG  - e13799
LID - 10.1111/petr.13799 [doi]
AB  - BACKGROUND: Renal graft thrombosis (RGT) is one of the main causes for early 
      graft loss in pediatric kidney transplantation (KTx). Despite the lack of 
      evidence-based recommendations, antithrombotic prophylaxis (aP) is used to 
      prevent RGT. METHODS: An online survey supported by the European Society for 
      Pediatric Nephrology was developed to investigate the current practice of aP in 
      pediatric KTx recipients <18 years. RESULTS: A total of 80 pediatric KTx centers 
      from 37 countries participated in the survey. Antithrombotic prophylaxis was 
      performed in 96% of the pediatric renal transplant centers (all/selected 
      patients: 54%/42%). The main overall used drugs were as follows: 
      low-molecular-weight heparin (89%), unfractionated heparin (UFH) (69%), and 
      acetylsalicylic acid (ASS) (55%). Ten different aP management strategies were 
      identified as follows: 51% used a single drug and 48% combined two drugs 
      sequentially. The corresponding centers started aP predominantly within 24 hours 
      after pediatric KTx; 51% preferred UFH for starting aP. In centers switching to a 
      second drug (51%), this change was performed after 10 +/- 6 days; of these 57% 
      preferred ASS for maintenance aP. Reported median aP duration was 51 days (range 
      1-360). CONCLUSIONS: Despite the use of aP in almost all responding pediatric KTx 
      centers, there is no uniform management strategy. Notwithstanding, UFH seems to 
      be the preferred drug for the early post-operative period of pediatric KTx, and 
      ASS for maintenance prophylaxis following pediatric KTx. Prospective studies are 
      needed to further evaluate the benefits and risks of aP, preferably resulting in 
      guidelines for the management in pediatric KTx.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Buder, Kathrin
AU  - Buder K
AD  - Pediatric Nephrology Department, University Children;s Hospital Zurich, Zurich, 
      Switzerland.
FAU - Zirngibl, Matthias
AU  - Zirngibl M
AD  - Department of General Pediatrics and Hematology/Oncology, University Hospital 
      Tubingen, University Children;s Hospital, Tubingen, Germany.
FAU - Bapistella, Sascha
AU  - Bapistella S
AD  - Department of General Pediatrics and Hematology/Oncology, University Hospital 
      Tubingen, University Children;s Hospital, Tubingen, Germany.
FAU - Nadalin, Silvio
AU  - Nadalin S
AD  - Department of General, Visceral and Transplant Surgery, University Hospital 
      Tubingen, Tubingen, Germany.
FAU - Tonshoff, Burkhard
AU  - Tonshoff B
AUID- ORCID: 0000-0002-6598-6910
AD  - Department of Pediatrics I, University Children's Hospital Heidelberg, 
      Heidelberg, Germany.
FAU - Weitz, Marcus
AU  - Weitz M
AUID- ORCID: 0000-0002-1696-5646
AD  - Department of General Pediatrics and Hematology/Oncology, University Hospital 
      Tubingen, University Children;s Hospital, Tubingen, Germany.
CN  - Members of the "Transplantation Working Group" of the European Society for 
      Paediatric Nephrology (ESPN)
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200818
PL  - Denmark
TA  - Pediatr Transplant
JT  - Pediatric transplantation
JID - 9802574
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Europe
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Follow-Up Studies
MH  - Graft Survival
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - *Nephrology
MH  - *Renal Artery
MH  - *Renal Veins
MH  - Retrospective Studies
MH  - *Societies, Medical
MH  - Thrombosis/*prevention & control
OTO - NOTNLM
OT  - antithrombotic prophylaxis
OT  - pediatric kidney transplantation
OT  - renal graft thrombosis
OT  - survey
EDAT- 2020/10/30 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/10/29 12:13
PHST- 2020/04/19 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/10/29 12:13 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
AID - 10.1111/petr.13799 [doi]
PST - ppublish
SO  - Pediatr Transplant. 2020 Nov;24(7):e13799. doi: 10.1111/petr.13799. Epub 2020 Aug 
      18.